SCHEMBL6098951

SCHEMBL6098951

O=C(N[C@@H]1C[C@@H]2CCN(C2)C1)c1cc(C(F)(F)F)c(F)cn1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 8/20 0.58
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38
CHRNB2 P17787 4/20 0.36
CHRNB4 P30926 4/20 0.36
CHRNA3 P32297 4/20 0.36
CHRNA4 P43681 4/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
USP30 Q70CQ3 1/20 0.35
RBP4 P02753 1/20 0.35
TTR P02766 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6098945 1.00 CHRNA7 (0.58) CHRNA7TAS1R3TAS1R1TAS1R2CHRNB2
SCHEMBL6100077 0.94 CHRNA7 (0.51) CHRNA7TAS1R3TAS1R1TAS1R2CHRNB2
SCHEMBL6101034 0.91 CHRNA7 (0.58) CHRNA7TAS1R3TAS1R1TAS1R2CHRNB2
SCHEMBL6101032 0.91 CHRNA7 (0.58) CHRNA7TAS1R3TAS1R1TAS1R2CHRNB2
SCHEMBL6100407 0.88 CHRNA7 (0.57) CHRNA7USP30
SCHEMBL6100403 0.88 CHRNA7 (0.57) CHRNA7USP30
SCHEMBL6100521 0.86 CHRNA7 (0.57) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6100526 0.86 CHRNA7 (0.57) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6100486 0.86 CHRNA7 (0.51) CHRNA7TAS1R3TAS1R1TAS1R2CHRNB2
SCHEMBL6098856 0.84 CHRNA7 (0.60) CHRNA7HTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001900-B2 Azabicyclic compounds for the treatment of disease PFIZER INC. (US) 2006-02-21 US claimed
US-20030236270-A1 Azabicyclic compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
US-7001900-B2 Azabicyclic compounds for the treatment of disease PFIZER INC. (US) 2006-02-21 US disclosed
EP-1478646-A1 AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 EP disclosed
US-20030236270-A1 Azabicyclic compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed
WO-2003072578-A1 AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236270-A1 Azabicyclic compounds for the treatment of disease MALT1, TPMT, CYP2B6 CHRNA7 1836/4885TAS1R3 4186/4885TAS1R1 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.